Rabia Cattie, MD
Hematology & Oncology · Camden, NJNPI 1053502732
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $28,730 of the $42,392 with a category attached, or 67.8%. 12 manufacturers reported payments, led by Merck at 50.0% of the total. 2025 is the largest year on record at $23,858, more than ten times the $314 reported in 2019. Among hematology & oncology clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 74 payments — averaging $572.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$21K
- AstraZeneca$21K
- Novartis$206
- Daiichi Sankyo Inc.$90
- Johnson & Johnson$72
- Beigene USA, Inc.$34
- plus $97 from 6 others
Across 5 payments — averaging $1054.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$5K
- Stemline Therapeutics Inc.$86
What the payments were for
- Consulting fees$8,71021%
- Speaking & faculty fees$28,73068%
- Travel & lodging$2,9477%
- Food & beverage$1,9905%
- Education$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 35 | $21,206 |
| AstraZeneca(2 entities) | 17 | $20,687 |
| Novartis | 8 | $206 |
| Daiichi Sankyo Inc. | 4 | $90 |
| Johnson & Johnson(2 entities) | 2 | $72 |
| Beigene USA, Inc. | 2 | $34 |
| AbbVie | 1 | $24 |
| Tempus AI, Inc | 1 | $18 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $15 |
| Astellas Pharma US Inc | 1 | $14 |
| Medtronic | 1 | $14 |
| Regeneron Healthcare Solutions, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$42,392 in reported general payments places this provider in the 90th percentile of 362 hematology & oncology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 24 | $386,144 |
| VerzenioAbemaciclib | 14 | $207,696 |
| EliquisApixaban | 11 | $8,675 |
| Exemestane | 44 | $5,194 |
| Tamoxifen Citrate | 72 | $2,391 |
| Anastrozole | 137 | $2,271 |
| Letrozole | 69 | $1,073 |
| Gabapentin | 27 | $305 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 19 | $233 |
| Alendronate Sodium | 30 | $218 |
| Dexamethasone | 13 | $117 |
| Olanzapine | 11 | $11 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Camden
- Peter GeorgesCamden$91K
- Ahmed Abou HusseinCamden$87K
- Michael RachshtutCamden$35K
- Generosa GranaCamden$34K
- Pallav MehtaCamden$22K
- Robert SpiegelWestfield$864K
- Amit PatelJersey City$770K
- Joshua StraussSpringfield$739K
- Charles FarberMorristown$609K
- Michael ScolaMorristown$506K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.